Tandem Diabetes Care (LTS:0M0F) Other Net Income (Loss): $-0 Mil (TTM As of Mar. 2026)


LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
67 GF Score
Price $14.23
GF Value $29.48
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Other Net Income (Loss)?

Tandem Diabetes Care LTS:0M0F -1.93% 67 Other Net Income (Loss) is $-0 Mil as of Mar. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 67/100 and a GF Value™ of $29.48 (Possible Value Trap). The stock has 5 warning signs investors should review.

Tandem Diabetes Care's Other Net Income (Loss) for the three months ended in Mar. 2026 was $0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0 Mil.

Tandem Diabetes Care's quarterly Other Net Income (Loss) declined from Sep. 2025 ($0 Mil) to Dec. 2025 ($-0 Mil) but then increased from Dec. 2025 ($-0 Mil) to Mar. 2026 ($0 Mil).

Tandem Diabetes Care's annual Other Net Income (Loss) stayed the same from Dec. 2023 ($0 Mil) to Dec. 2024 ($0 Mil) but then declined from Dec. 2024 ($0 Mil) to Dec. 2025 ($-0 Mil).

Tandem Diabetes Care Other Net Income (Loss) Related Terms

Tandem Diabetes Care Other Net Income (Loss) Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Other Net Income (Loss) Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
LTS:0M0F
67GF Score
Tandem Diabetes Care Inc LTS:0M0F
Other Net Income (Loss) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Net Income (Loss) of $-0 Mil mean?
Tandem Diabetes Care (LTS:0M0F) has a Other Net Income (Loss) of $-0 Mil as of Mar. 2026.
Is Tandem Diabetes Care's Other Net Income (Loss) too high?
Tandem Diabetes Care's current Other Net Income (Loss) is $-0 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Other Net Income (Loss) compare to ATEC and BFLY?
Tandem Diabetes Care's Other Net Income (Loss) of $-0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Net Income (Loss) for a Medical Devices & Instruments company?
A good Other Net Income (Loss) depends on the Medical Devices & Instruments industry context. However, Other Net Income (Loss) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Net Income (Loss) mean?
A high Other Net Income (Loss) can signal that a stock is expensive relative to its fundamentals. Tandem Diabetes Care's current Other Net Income (Loss) is $-0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.48, compared to a current price of $14.23 — trading 51.7% below its estimated fair value. The current Other Net Income (Loss) is $-0 Mil. Tandem Diabetes Care's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Net Income (Loss) calculated?
Other Net Income (Loss) is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Other Net Income (Loss) is $-0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $14.23 is trading 51.7% below its estimated GF Value™ of $29.48. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • Other Net Income (Loss): $-0 Mil
  • GF Value™: $29.48 vs. price of $14.23 (51.7% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
67GF Score

Get the complete analysis for LTS:0M0F

Other Net Income (Loss) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.23
Price
$29.48
GF Value